Overview

SPD489 Low Dose and High Dose Ranges When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia

Status:
Terminated

Trial end date:
2013-04-01

Target enrollment:

Participant gender:

Summary

The primary purpose of this study is to determine whether SPD489 low dose range (40, 80, or 100mg) and high dose range (120, 140, or 160mg) are effective in the treatment of Negative Symptoms.

Phase:

Phase 3

Details

Lead Sponsor:

Shire

Treatments:

Antipsychotic Agents
Lisdexamfetamine Dimesylate